Axa’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Axa’s Portfolio GBT Stock Details GBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-42,300	Closed	-$2.33M	–	1376
2020 Q3	$2.33M	Hold	42,300	–	–	0.01%	788
2020 Q2	$2.67M	Buy	+42,300	New	+$2.9M	0.01%	763
2018 Q3	–	Sell	-5,100	Closed	-$231K	–	1409
2018 Q2	$231K	Sell	5,100 -19,700	-79%	-$897K	﹤0.01%	1285
2018 Q1	$1.2M	Buy	+24,800	New	+$1.38M	﹤0.01%	958

Other funds holding GBT

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAMU

Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Axa's GBT Position: Q4 2020 in Review

Axa sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2020, closing a stake of 42,300 shares — an estimated $2.33M sold.

Axa first reported a position in GBT in Q1 2018 and held it in 4 quarters. The position peaked at $2.67M in Q2 2020. 228 funds tracked by Wall St. Rank hold GBT as of Q4 2020.

Axa reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2020 after selling out during the quarter.
Axa sold 42,300 Global Blood Therapeutics, Inc. shares in Q4 2020, an estimated $2.33M.
Axa first reported a position in Global Blood Therapeutics, Inc. in Q1 2018 and held it in 4 quarters.
Axa's Global Blood Therapeutics, Inc. position peaked at $2.67M in Q2 2020.
228 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2020.

Based on Axa's 13F filing for Q4 2020, filed 12 Feb 2021.